BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38521471)

  • 1. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
    Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
    Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
    Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
    El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
    Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-(4-Methoxybenzylidene)thiazolidine-2,4-dione-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
    El-Adl K; Sakr H; Nasser M; Alswah M; Shoman FMA
    Arch Pharm (Weinheim); 2020 Sep; 353(9):e2000079. PubMed ID: 32515896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies.
    Elkady H; Abuelkhir AA; Rashed M; Taghour MS; Dahab MA; Mahdy HA; Elwan A; Al-Ghulikah HA; Elkaeed EB; Ibrahim IM; Husein DZ; Metwaly A; Eissa IH
    Comput Biol Chem; 2023 Dec; 107():107958. PubMed ID: 37714080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
    Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
    Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
    Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
    Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
    Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semi-synthesized anticancer theobromine derivatives targeting VEGFR-2:
    Dahab MA; Mahdy HA; Elkady H; Taghour MS; Elwan A; Elkady MA; Elsakka EGE; Elkaeed EB; Alsfouk AA; Ibrahim IM; Metwaly AM; Eissa IH
    J Biomol Struct Dyn; 2024 May; 42(8):4214-4233. PubMed ID: 37261471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
    Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
    Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
    Aziz NAAM; George RF; El-Adl K; Mahmoud WR
    Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
    Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway.
    Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Elkaeed EB; Alsfouk BA; Alesawy MS; Husein DZ; Metwaly AM; Eissa IH
    PLoS One; 2022; 17(9):e0272362. PubMed ID: 36149902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects.
    Elkaeed EB; Yousef RG; Elkady H; Gobaara IMM; Alsfouk BA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents.
    El-Metwally SA; Abou-El-Regal MM; Eissa IH; Mehany ABM; Mahdy HA; Elkady H; Elwan A; Elkaeed EB
    Bioorg Chem; 2021 Jul; 112():104947. PubMed ID: 33964580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.